2025-01-12 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

This report analyzes Merck & Co Inc (MRK), a leading pharmaceutical company, based on the provided data.

**1. Performance Relative to S&P 500 (VOO):**

Merck & Co Inc is a global healthcare company known for its pharmaceutical and vaccine products.

The cumulative return of MRK (63.85%) lags behind the S&P 500 (VOO) cumulative return (112.20%) by 48.3 percentage points.  The relative divergence, considering historical volatility, places MRK at the 13.8th percentile relative to the S&P 500. This indicates underperformance compared to the broader market.  The provided alpha consistently shows negative values (-0.1), suggesting underperformance compared to the market benchmark even when considering risk (beta).  Beta values fluctuate significantly from 110 to 268, indicating high sensitivity to market movements.

**2. Recent Price Movement:**

* **Closing Price:** $99.25
* **5-Day Moving Average:** $99.80
* **20-Day Moving Average:** $99.55
* **60-Day Moving Average:** $100.97

The current price is slightly below the 5-day and 20-day moving averages, and significantly below the 60-day moving average, suggesting a short-term downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 54.11 (Slightly above neutral, suggesting neither overbought nor oversold conditions)
* **PPO:** 0.12 (Positive, indicating bullish momentum)
* **20-Day Relative Divergence Change:** +1.4 (Short-term upward trend)
* **Expected Return (2+ years):** 37.8% (This represents an expected outperformance compared to the S&P 500 over the long term.  However, this projection needs further validation and context.)


The current price of $99.25 doesn't indicate any dramatic recent price swings (no evidence of a sharp surge or drop is presented).

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in EPS and revenue. While revenue generally shows an increasing trend, EPS fluctuates.  There is a duplicated entry for 2024-11-06 which needs clarification.  Further analysis is required to determine the underlying causes of these fluctuations.  A more complete picture would require additional financial information.

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66B       |
| 2024-08-05 | 2.15 | $16.11B       |
| 2024-05-03 | 1.88 | $15.78B       |
| 2023-11-03 | 1.87 | $15.96B       |
| 2024-11-06 | 1.87 | $15.96B       |


**5. Financial Information:**

The financial data shows a generally healthy financial position for MRK, though profitability fluctuates.  Profit margins are high but slightly decreased recently.  ROE (Return on Equity) has also been inconsistent, indicating variations in profitability and the efficiency of utilizing shareholder equity.  Further investigation is needed to ascertain the reasons for these fluctuations.

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |
| 2023-09-30 | $15.96B    | 73.29%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE           |
|------------|-------------|---------------|
| 2024-09-30 | $44.50B     | 7.09%         |
| 2024-06-30 | $43.58B     | 12.52%        |
| 2024-03-31 | $40.36B     | 11.80%        |
| 2023-12-31 | $37.58B     | -3.26%        |
| 2023-09-30 | $41.25B     | 11.50%        |


**7. Overall Summary:**

Merck (MRK) shows inconsistent performance compared to the S&P 500. While possessing high profit margins and generally healthy financial information,  recent earnings and ROE show volatility. The current price is slightly below recent moving averages, hinting at a short-term bearish trend.  The long-term projected return is positive, but requires further investigation and due diligence.  A deeper analysis of the financial statements, competitive landscape, and future pipeline is necessary for a comprehensive evaluation. The duplicated earnings data entry requires clarification.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing involves risk, including the potential loss of principal.  Conduct thorough research and consult a financial advisor before making any investment decisions.
